ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The acquisitive Shire followed its $75 million purchase of Fibrotech earlier this month with an announcement last week that it will pay $260 million for Lumena Pharmaceuticals, a rare disease drug firm. Lumena’s lead candidates include LUM001, a treatment for four hepatic diseases—two pediatric and two adult—and LUM002, which has completed Phase I trials for nonalcoholic steatohepatitis. Last year, Dublin-based Shire acquired another rare disease specialist, ViroPharma, for $4.2 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X